Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.49 |
| ▸ | DGKA | P23743 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 4/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | PAM | P19021 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ether SCHEMBL6543929 | 0.91 | MGLL (0.46) | MGLLDGKAALDH1A1TSHRADRA2A | |
| SCHEMBL31366939 | 0.88 | EPHX2 (0.47) | MGLLDGKAALDH1A1TSHRADRA2A | |
| SCHEMBL1760113 | 0.86 | MGLL (0.43) | MGLLDGKAALDH1A1TSHRADRA2A | |
| 2-Ethoxyethanol SCHEMBL6685782 | 0.84 | ALDH1A1 (0.47) | MGLLDGKAALDH1A1TSHRDNM1 | |
| SCHEMBL822152 | 0.84 | MGLL (0.52) | MGLLDGKATSHRADRA2AADRA1A | |
| SCHEMBL206255 | 0.84 | DGKA (0.56) | MGLLDGKATSHRADRA2AADRA1A | |
| SCHEMBL11647199 | 0.83 | TSHR (0.65) | MGLLDGKAALDH1A1TSHRADRA2A | |
| SCHEMBL12200854 | 0.83 | DGKA (0.52) | MGLLDGKAALDH1A1TSHRADRA2A | |
| SCHEMBL20210449 | 0.83 | DGKA (0.57) | MGLLDGKAALDH1A1TSHRADRA2A | |
| SCHEMBL9298318 | 0.82 | MGLL (0.47) | MGLLDGKATSHRADRA2AADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200368330-A1 | MODIFIED HYALURONIDASES AND USES IN TREATING HYALURONAN-ASSOCIATED DISEASES AND CONDITIONS | HALOZYME THERAPEUTICS, INC. | 2020-11-26 | — | — | US | claimed |
| US-20190336587-A1 | MODIFIED HYALURONIDASES AND USES IN TREATING HYALURONAN-ASSOCIATED DISEASES AND CONDITIONS | HALOZYME THERAPEUTICS, INC. | 2019-11-07 | — | — | US | claimed |
| US-10328130-B2 | Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions | HALOZYME, INC. (US) | 2019-06-25 | — | — | US | claimed |
| EP-3192525-A1 | MODIFIED HYALURONIDASES FOR USE IN TREATING HYALURONAN-ASSOCIATED DISEASES AND CONDITIONS | Halozyme, Inc. (US) | 2017-07-19 | — | — | EP | claimed |
| WO-2014062856-A1 | HYPOXIA AND HYALURONAN AND MARKERS THEREOF FOR DIAGNOSIS AND MONITORING OF DISEASES AND CONDITIONS AND RELATED METHODS | HALOZYME, INC. (US) | 2014-04-24 | — | — | WO | claimed |
| EP-2662090-A1 | Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions | Halozyme, Inc. (US) | 2013-11-13 | — | — | EP | claimed |
| US-20130028856-A9 | Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions | FROST GREGORY I (US) | 2013-01-31 | — | — | US | claimed |
| US-20120171153-A1 | Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions | HALOZYME, INC. | 2012-07-05 | — | — | US | claimed |
| EP-2285402-A2 | MODIFIED HYALURONIDASES AND USES IN TREATING HYALURONAN-ASSOCIATED DISEASES AND CONDITIONS | Halozyme, Inc. (US) | 2011-02-23 | — | — | EP | claimed |
| US-20100003238-A1 | Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions | HALOZYME THERAPEUTICS, INC. | 2010-01-07 | — | — | US | claimed |
| WO-2009128917-A2 | MODIFIED HYALURONIDASES AND USES IN TREATING HYALURONAN-ASSOCIATED DISEASES AND CONDITIONS | HALOZYME, INC. (US) | 2009-10-22 | — | — | WO | claimed |
| EP-3943501-A1 | SOLUBLE GLYCOSAMINOGLYCANASES AND METHODS OF PREPARING AND USING SOLUBLE GLYCOSAMINOGLYCANASES | Halozyme, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
| US-20200368330-A1 | MODIFIED HYALURONIDASES AND USES IN TREATING HYALURONAN-ASSOCIATED DISEASES AND CONDITIONS | HALOZYME THERAPEUTICS, INC. | 2020-11-26 | — | — | US | disclosed |
| US-10588983-B2 | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases | HALOZYME, INC. (US) | 2020-03-17 | — | — | US | disclosed |
| US-20190351031-A1 | METHODS OF SELECTING SUBJECTS FOR COMBINATION CANCER THERAPY WITH A POLYMER-CONJUGATED SOLUBLE PH20 | HALOZYME, INC. | 2019-11-21 | — | — | US | disclosed |
| WO-2009128917-A2 | MODIFIED HYALURONIDASES AND USES IN TREATING HYALURONAN-ASSOCIATED DISEASES AND CONDITIONS | HALOZYME, INC. (US) | 2009-10-22 | — | — | WO | disclosed |
| US-20090123367-A1 | Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases | DELFMEMS (FR) | 2009-05-14 | — | — | US | disclosed |
| EP-1858926-A1 | SOLUBLE GLYCOSAMINOGLYCANASES AND METHODS OF PREPARING AND USING SOLUBLE GLYCOSAMINOGLYCANASES | Halozyme Therapeutics, Inc. (US) | 2007-11-28 | — | — | EP | disclosed |
| WO-2006091871-A1 | SOLUBLE GLYCOSAMINOGLYCANASES AND METHODS OF PREPARING AND USING SOLUBLE GLYCOSAMINOGLYCANASES | HALOZYME THERAPEUTICS, INC. (US) | 2006-08-31 | — | — | WO | disclosed |
| US-20060104968-A1 | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases | HALOZYME, INC. (US) | 2006-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190336587-A1 | MODIFIED HYALURONIDASES AND USES IN TREATING HYALURONAN-ASSOCIATED DISEASES AND CONDITIONS | CD44, HPSE, ENGASE | MGLL 1027/4885DGKA 2459/4885ALDH1A1 405/4885 |
| US-20120171153-A1 | Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions | CD44, HPSE, ENGASE | MGLL 1027/4885DGKA 2459/4885ALDH1A1 405/4885 |
| US-20130028856-A9 | Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions | CD44, HPSE, ENGASE | MGLL 1027/4885DGKA 2459/4885ALDH1A1 405/4885 |
| US-20200368330-A1 | MODIFIED HYALURONIDASES AND USES IN TREATING HYALURONAN-ASSOCIATED DISEASES AND CONDITIONS | CD44, HPSE, ENGASE | MGLL 1027/4885DGKA 2459/4885ALDH1A1 405/4885 |
| US-10328130-B2 | Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions | CD44, HPSE, ENGASE | MGLL 1027/4885DGKA 2459/4885ALDH1A1 405/4885 |
| US-20100003238-A1 | Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions | CD44, HPSE, ENGASE | MGLL 1027/4885DGKA 2459/4885ALDH1A1 405/4885 |
| US-20190351031-A1 | METHODS OF SELECTING SUBJECTS FOR COMBINATION CANCER THERAPY WITH A POLYMER-CONJUGATED SOLUBLE PH20 | MMP20, CD44, FOLH1 | MGLL 2850/4885DGKA 3567/4885ALDH1A1 625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.